Search filters
Termination Reimbursement scheme Forxiga®/Xigduo® - Diabetes

Termination Reimbursement scheme Forxiga®/Xigduo® - Diabetes

30/07/2025

As from the 1st of August 2025 the “bijlage 2 voorwaarden” for Forxiga® and Xigduo® have been withdrawn. This means that per 1st...

Termination Reimbursement scheme  Cresemba® 40 mg en 100mg

Termination Reimbursement scheme Cresemba® 40 mg en 100mg

23/07/2025

From August 1st 2025 onwards, Cresemba® 40 mg en 100mg is fully reimbursed by the health insurer. Therefore the...

Update Reimbursement Scheme Cresemba®

Update Reimbursement Scheme Cresemba®

28/02/2025

The health insurer does not fully reimburse Cresemba® 40 mg and 100 mg. The producer of this medicine has therefore asked TBR...

Update Reimbursement Scheme Metoject®

Update Reimbursement Scheme Metoject®

15/11/2024

From January 1, 2025 the use of Metoject Pen® 7.5mg will be fully reimbursed by the Health Insurer. For this reason the...

Reimbursement Scheme Mounjaro KwikPen® for the indication Diabetes Mellitus type 2

Reimbursement Scheme Mounjaro KwikPen® for the indication Diabetes Mellitus type 2

06/11/2024

The health insurer does not fully reimburse Mounjaro KwikPen for the indication Diabetes Mellitus type 2. The producer of this...

You are currently offline. Some pages or content may fail to load.